CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $6.08B, above the global median of $1.18B
- FinancialsAltman Z-Score 6.88: safe zone
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.08BUSDvs all stocks (USD)
Revenue (TTM)
618.07MUSDvs all stocks (USD)
Profit Margin
-139.18%vs Biotechnology peers
Beta
0.5070xvs all stocks
52-Week Change
32.07%vs all stocks
Market Capitalization
6.08BUSDvs all stocks (USD)
Enterprise Value
6.69BUSDvs all stocks (USD)
Forward P/E
-282.92xvs Biotechnology peers
Price to Sales (TTM)
9.68xvs Biotechnology peers
Enterprise to Revenue
10.83xvs Biotechnology peers
Enterprise to EBITDA
-95.23xvs Biotechnology peers
Gross Margin
82.78%vs Biotechnology peers
Profit Margin
-139.18%vs Biotechnology peers
Operating Margin
-14.81%vs Biotechnology peers
Return on Assets (TTM)
-6.79%vs Biotechnology peers
Revenue (TTM)
618.07MUSDvs all stocks (USD)
Revenue per Share (TTM)
11.02USDUpdated Aug 28, 2026Quarterly Revenue Growth
37.90%vs Biotechnology peers
Gross Profit (TTM)
505.11MUSDvs all stocks (USD)
EBITDA (TTM)
17.21MUSDvs all stocks (USD)
Net Income (TTM)
-860.21MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
37.92%vs Biotechnology peers
Operating Cash Flow (TTM)
-227.27MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
76.62MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
521.31MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
100.24MUSDFY2025 · Dec 31, 2025Gross Profit
421.07MUSDFY2025 · Dec 31, 2025Operating Income
-22.14MUSDvs all stocks (USD)
Pre-tax Income
-21.43MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.94MUSDFY2025 · Dec 31, 2025Net Income
-23.36MUSDFY2025 · Dec 31, 2025EBIT
-7.04MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
17.21MUSDFY2025 · Dec 31, 2025Research & Development
186.18MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
257.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
14.39MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.4700USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.4700USDFY2025 · Dec 31, 2025Basic Shares Outstanding
50.20MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
50.20MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-23.36MUSDFY2025 · Dec 31, 2025Operating Cash Flow
60.41MUSDFY2025 · Dec 31, 2025Free Cash Flow
59.46MUSDDerived from operating cash flow minus capital expenditure. This filing charges 24.24M of depreciation against 954K of capital expenditure, and its own free-cash-flow line reads 54.87M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
298.17MUSDFY2025 · Dec 31, 2025Income Tax Paid
2.16MUSDFY2025 · Dec 31, 2025Interest Paid
12.65MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-23.36MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
24.24MUSDFY2025 · Dec 31, 2025Stock-based Compensation
71.42MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.07MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-48.05MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
50.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-16.01MUSDFY2025 · Dec 31, 2025Capital Expenditures
-954.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-97.42MUSDFY2025 · Dec 31, 2025Sale of Investments
74.42MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-23.95MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
60.93MSharesUpdated Aug 28, 2026Float Shares
56.42MSharesUpdated Aug 28, 2026Shares Short
6.49MSharesUpdated Aug 28, 2026Short Ratio
9.12daysvs all stocks
Short % of Shares Outstanding
13.96%vs all stocks
% Held by Insiders
1.29%vs all stocks
% Held by Institutions
111.94%vs all stocks
Total Cash (MRQ)
438.29MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.75USDUpdated Aug 28, 2026Total Debt (MRQ)
762.95MUSDvs all stocks (USD)
Current Ratio (MRQ)
2.86xvs Biotechnology peers
Book Value per Share (MRQ)
-0.1610USDUpdated Aug 28, 2026Total Assets
842.81MUSDvs all stocks (USD)
Total Current Assets
549.68MUSDFY2025 · Dec 31, 2025Total Liabilities
528.12MUSDFY2025 · Dec 31, 2025Total Non-current Assets
293.13MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
322.32MUSDFY2025 · Dec 31, 2025Total Current Liabilities
205.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
296.68MUSDFY2025 · Dec 31, 2025Other Short-term Investments
86.64MUSDFY2025 · Dec 31, 2025Accounts Receivable
123.33MUSDFY2025 · Dec 31, 2025Inventory
24.89MUSDFY2025 · Dec 31, 2025Accounts Payable
9.61MUSDFY2025 · Dec 31, 2025Short-term Debt
2.14MUSDFY2025 · Dec 31, 2025Long-term Debt
317.31MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
5.01MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-667.54MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
314.69MUSDvs all stocks (USD)
52-Week Low
63.23USDUpdated Aug 28, 202652-Week High
130.00USDUpdated Aug 28, 202652-Week Change
32.07%vs all stocks
Beta
0.5070xvs all stocks
50-Day MA
110.47USDUpdated Aug 28, 2026200-Day MA
94.76USDUpdated Aug 28, 2026Avg 10-Day Volume
529.44KSharesUpdated Aug 28, 2026Avg 30-Day Volume
658.88KSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-14.28USDUpdated Aug 28, 2026Other Income / Expense
2.37MUSDFY2025 · Dec 31, 20255 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.83Profit Margin: -1.39
Financial Health
Altman Z-Score 6.88: safe zoneNotable
Altman Z-Score: 6.88
High structural barrier to entryNotable
Barrier to Entry: 1.46
Consistent revenue growth patternNotable
Growth Consistency Score: 0.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $6.08B, above the global median of $1.18BNotable
Market cap (USD): 6,082,877,393Global Median: 1,179,398,897.704
Revenue is $618.07M, above the global median of $534.05MNotable
Revenue (USD): 618,067,008Global Median: 534,052,387.958
Levered free cash flow is $76.62M, above the global median of $19.19MNotable
Levered free cash flow (USD): 76,618,128Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Liquidia Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Travere Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
XPEL, Inc.
4 interpretationsFCF Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
ResMed Inc.
4 interpretationsFCF Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
WD-40 Company
4 interpretationsFCF Ratios ElevatedRevenue Growing With Receivables GrowingIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated